【摘要】 目的:分析非小细胞肺癌(non-small cell lung cancer,NSCLC)患者β-tubulin Ⅲ的表达水平与化学治疗(化疗)敏感性的关系。方法:经病理确诊的晚期NSCLC患者以1:2随机分配至对照组和基因型组:对照组使用吉西他滨联合顺铂化疗;基因型组根据ERCC1及RRM1的表达情况进行个体化治疗。检测病理标本中β-tubulin Ⅲ的表达水平,比较β-tubulin Ⅲ蛋白表达水平与临床疗效之间的关系。结果:基因型组最终有118例NSCLC病例可评价,均可成功检测β-tubulin Ⅲ的表达情况。对照组有效率(37.5%)与基因型组有效率(47.5%)比较,差异无统计学意义(P>0.05)。基因型组中各组间有效率比较,差异无统计学意义(P>0.05);但β-tubulinⅢ低表达组有效率(55.1%)显著高于β-tubulin Ⅲ高表达组(36.7%,P<0.05)。结论:在晚期NSCLC腺癌亚型中,β-tubulin Ⅲ低表达患者疗效较好,β-tubulin Ⅲ高表达可能意味着对多西他赛耐药。更多还原

【Abstract】 Objective:To analyze the relation between β-tubulin Ⅲ expression level and chemosensitivity in non-small cell lung cancer(NSCLC).Methods:The patients were divided into a control group and a genotype group with a proportion of 1:2.The control group received the treatment of gemcitabin and cisplatin,while the genotype group received individual therapy according to the level of ERCC1 and RRM1.The correlation between β-tubulin Ⅲ expression level and chemosensitivity in NSCLC was analyzed.Results:β-Tubulin Ⅲ expression was detected in all patients in the genotype group.Compared with the genotype group(47.5%),efficiency in the control group(37.5%) was not significantly different.Efficiency in patients with low expression of β-tubulin Ⅲ was significantly higher than that of patients with high expression of β-tubulin Ⅲ(55.1% vs 36.7%,P<0.05).Conclusion:In advanced NSCLC subtypes,patients with low expression of β-tubulin Ⅲ have good therapeutic effect.High β-tubulin Ⅲ expression may indicate resistance to docetaxel.更多还原